Evidence of an environmental effect on survival in ALS

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 15, Issue 7-8, 2014, Pages 528-533

  Keren, Noa ^a   Scott, Kirsten M ^b   Tsuda, Miho ^a   Barnwell, Jessica ^c   Knibb, Jonathan A ^d   Ellis, Cathy M ^e   Leigh, P Nigel ^f   Shaw, Christopher E ^g   Al Chalabi, Ammar ^g  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c NORTH MIDDLESEX UNIVERSITY HOSPITAL NHS TRUST   (United Kingdom)

^d ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

^f UNIVERSITY OF SUSSEX   (United Kingdom)

^g KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Amyotrophic lateral sclerosis; Cluster; Motor neuron disease; Population study; Survival

Indexed keywords

RILUZOLE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARM DISEASE; ARTICLE; BULBAR PARALYSIS; DELAYED DIAGNOSIS; DRUG USE; FEMALE; FLAIL LEG SYNDROME; HUMAN; LEG DISEASE; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PHENOTYPE; POPULATION RESEARCH; PRIMARY LATERAL SCLEROSIS; PROGRESSIVE MUSCULAR ATROPHY; PROSPECTIVE STUDY; REGISTER; RETROSPECTIVE STUDY; RURAL AREA; SURVIVAL; UNITED KINGDOM; ANALYSIS OF VARIANCE; ENVIRONMENT; HEALTH CARE PLANNING; MIDDLE AGED; MORTALITY; NONPARAMETRIC TEST; RESIDENTIAL CARE;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANALYSIS OF VARIANCE; CATCHMENT AREA (HEALTH); COMMUNITY HEALTH PLANNING; ENGLAND; ENVIRONMENT; FEMALE; HUMANS; MALE; MIDDLE AGED; REGISTRIES; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS;

EID: 84914708072     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/21678421.2014.911326     Document Type: Article

References (49)

1. Sabel CE, Boyle P, Loytonen M, Gatrell AC, Jokelainen M, Flowerdew R, et al. Spatial clustering of amyotrophic lateral sclerosis in Finland at place of birth and place of death. Am J Epidemiol. 2003;157:898-905.
2. Johnston CA, Stanton BR, Turner MR, Gray R, Blunt AH, Butt D, et al. Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol. 2006;253:1642-3.
3. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942-55.
4. Byrne S, Walsh C, Lynch C, Bede P, Elamin M, Kenna K, et al. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2010;82:623-7.
5. Scotton WJ, Scott KM, Moore DH, Almedom L, Wijesekera LC, Janssen A, et al. Prognostic categories for amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012;13:502-8
6. Chiò A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al., on behalf of the EURALS Consortium Prognostic Factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10:310-23.
7. Gordon PH, Cheng B, Salachas F, Pradat PF, Bruneteau G, Corcia P, et al. Progression in ALS is not linear but is curvilinear. J Neurol. 2010;257:1713-7.
8. Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron. 2006;52:39-59.
9. Abhinav K, Stanton B, Johnston C, Hardstaff J, Orrell R, Howard R, et al. Amyotrophic Lateral Sclerosis in South-East England: A Population Based Study. Neuroepidemiology. 2007;29:44-8.
10. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial 'Clinical limits of amyotrophic lateral sclerosis' workshop contributors. J Neurol Sci. 1994;124 (Suppl):96-107.
11. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293-9.
12. Caroscio JT, Calhoun WF, Yahr MD. Prognostic factors in motor neuron disease: a prospective study of longevity. In: Rose FC, editor. Research progress in motor neuron disease. Pitman: London; 1984. pp. 34-43.
13. Preux PM, Couratier P, Boutros-Toni F, Salle JY, Tabaraud F, Bernet-Bernady P, et al. Survival prediction in sporadic amyotrophic lateral sclerosis. Age and clinical form at onset are independent risk factors. Neuroepidemiology. 1996;15:153-60.
14. Louwerse ES, Visser CE, Bossuyt PM, Weverling GJ. Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors. The Netherlands ALS Consortium. J Neurol Sci. 1997;152(Suppl 1):S10-7.
15. Testa D, Lovati R, Ferrarini M, Salmoiraghi F, Filippini G. Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:208-12.
16. Christensen PB, Hojer-Pedersen E, Jensen NB. Survival of patients with amyotrophic lateral sclerosis in two Danish counties. Neurology. 1990;40:600-4.
17. Chio A, Mora G, Leone M, Mazzini L, Cocito D, Giordana MT, et al. Early symptom progression rate is related to ALS outcome: a prospective population based study. Neurology. 2002;59:99-103.
18. del Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis: a population based study. Neurology. 2003;60:813-9.
19. Millul A, Beghi E, Logroscino G, Micheli A, Vitelli E, Zardi A. Survival of patients with amyotrophic lateral sclerosis in a population based registry. Neuroepidemiology. 2005;25:114-9.
20. Forbes RB, Colville S, Swingler RJ, Scottish ALSMNDR. The epidemiology of amyotrophic lateral sclerosis (ALS/MND) in people aged 80 years or over. Age Ageing. 2004;33:131-4.
21. Uebayashi Y, Yase Y, Tnaka H, Shimada Y, Toyojura Y. Prognosis of motor neuron disease in Japan. Neuroepidemiology. 1983;2:243-56.
22. Taylor JA, Davis JP. Evidence for clustering of amyotrophic lateral sclerosis in Wisconsin. J Clin Epidemiol. 1989;42:569-75.
23. Kokubo Y, Kuzuhara S, Narita Y. Geographical distribution of amyotrophic lateral sclerosis with neurofi brillary tangles in the Kii Peninsula of Japan. J Neurol. 2000;247:850-2.
24. Betemps EJ, Buncher CR. Birthplace as a risk factor in motor neuron disease and Parkinson's disease. Int J Epidemiol. 1993;22:898-904.
25. Gunnarsson LG, Lygner PE, Veiga-Cabo J, de Pedro-Cuesta J. An epidemic-like cluster of motor neuron disease in a Swedish county during the period 1973-1984. Neuroepidemiology. 1996; 15:142-52.
26. Uccelli R, Binazzi A, Altavista P, Belli S, Comba P, Mastrantonio M, et al. Geographic distribution of amyotrophic lateral sclerosis through motor neuron disease mortality data. Eur J Epidemiol. 2007;22:781-90.
27. Mitchell JD, Gatrell AC, Al-Hamad A, Davies RB, Batterby G. Geographical epidemiology of residence of patients with motor neuron disease in Lancashire and south Cumbria. J Neurol Neurosurg Psychiatry. 1998;65:842-7.
28. Scott KM, Abhinav K, Stanton BR, Johnston C, Turner MR, Ampong MA, et al. Geographical clustering of amyotrophic lateral sclerosis in south-east England: a population study. Neuroepidemiology. 2009;32:81-8.
29. Doi Y, Yokoyama T, Tango T, Takahashi K, Fujimoto K, Nakano I. Temporal trends and geographic clusters of mortality from amyotrophic lateral sclerosis in Japan, 1995-2004. J Neurol Sci. 2010; 298:78-84.
30. Alonso V, Villaverde-Hueso A, Hens MJ, Morales-Piga A, Abaitua I, de la Paz MP. Increase in motor neuron disease mortality in Spain: temporal and geographical analysis (1990-2005). Amyotroph Lateral Scler. 2011;12:192-8.
31. Noonan CW, White MC, Thurman D, Wong LY. Temporal and geographic variation in United States motor neuron disease mortality, 1969-1998. Neurology. 2005; 64:1215-21.
32. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2007 ;CD 001447.
33. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330:585-91.
34. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347:1425-31.
35. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995;118:707-19.
36. Paillisse C, Lacomblez L, Dib M, Bensimon G, Garcia-Acosta S, Meininger V. Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6:37-44.
37. Czaplinski A, Yen AA, Appel SH. Amyotrophic lateral sclerosis: early predictors of prolonged survival. J Neurol. 2006;253:1428-36.
38. Tysnes OB, Vollset SE, Aarli JA. Epidemiology of amyotrophic lateral sclerosis in Hordaland county, western Norway. Acta Neurol Scand. 1991;83:280-5.
39. Thijs V, Peeters E, Theys P, Matthijs G, Robberecht W. Demographic characteristics and prognosis in a Flemish amyotrophic lateral sclerosis population. Acta Neurol Belg. 2000;100:84-90.
40. Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, et al. The ALSFRS-R predicts survival time in an ALS clinic population. Neurology. 2005;64:38-43.
41. Beghi E, Millul A, Logroscino G, Vitelli E, Micheli A, Slalom G. Outcome measures and prognostic indicators in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2008;9:163-7.
42. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman OM. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: a population based study. Arch Neurol. 2000;57:1171-6.
43. Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3:15-21.
44. Turner MR, Parton MJ, Shaw CE, Leigh PN, Al-Chalabi A. Prolonged survival in motor neuron disease: a descriptive study of the King's database 1990-2002. J Neurol Neurosurg Psychiatry. 2003;74:995-7.
45. Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve. 2002;25:709-14.
46. Chancellor AM, Slattery JM, Fraser H, Swingler RJ, Holloway SM, Warlow CP. The prognosis of adult-onset motor neuron disease: a prospective study based on the Scottish Motor Neuron Disease Register. J Neurol.1993;240:339-46.
47. Nelson LM, McGuire V, Longstreth WT Jr, Matkin C. Population based case-control study of amyotrophic lateral sclerosis in western Washington State. I. Cigarette smoking and alcohol consumption. Am J Epidemiol. 2000;151:156-63.
48. Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000. J Neurol Neurosurg Psychiatry. 2003;74:1258-61.
49. Sutedja NA, Veldink JH, Fischer K, Kromhout H, Wokke JH, Huisman MH, et al. Lifetime occupation, education, smoking, and risk of ALS. Neurology. 2007;69:1508-14.